S. Papapoulos

发表

Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone.

H. Vloedgraven, W. Grzesik, P. Robey, 1996, Cancer research.

Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research

Klaus Klaushofer, Piet Geusens, Regis O'Keefe, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Low‐energy fractures of the humeral shaft and bisphosphonate use

M. Yavropoulou, A. Giusti, S. Dijkstra, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features.

O. Dekkers, A. Giusti, S. Dijkstra, 2011, Bone.

Report on Osteoporosis in the European Community: Current Status and Recommendations for the Future

S. Papapoulos, J. Compston, F. Blanchard, 1998, Osteoporosis International.

Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation.

Ting-Kai Chang, Kilannin Krysiak, Mitsuo Ochi, 2009, Journal of the American Chemical Society.

Taxonomy of rare genetic metabolic bone disorders

J. Kaufman, N. Watts, J. Bilezikian, 2015, Osteoporosis International.

Impact Microindentation Assesses Subperiosteal Bone Material Properties in Humans.

P. Chavassieux, B. Misof, E. Paschalis, 2020, Bone.

Sclerostin Deficiency Is Linked to Altered Bone Composition

A. Roschger, P. Roschger, E. Paschalis, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo.

J. Drijfhout, P. Quax, H. Vloedgraven, 2001, The American journal of pathology.

Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo.

Ivo Que, Antoinette Wetterwald, A. Wetterwald, 2005, Cancer research.

Chapter 7 BMP 7 , a Putative Regulator of Epithelial Homeostasis in the Human Prostate , is a Potent Inhibitor of Prostate Cancer Bone Metastasis In Vivo

S. Vukicevic, P. Dijke, F. Borovečki, 2009 .

Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease

S. Papapoulos, C. Lowik, F. Ebetino, 2009, Breast Cancer Research and Treatment.

Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate

C. Löwik, S. Papapoulos, K. Hoekman, 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Novel approaches to the treatment of osteoporosis.

S. Papapoulos, N. Appelman-Dijkstra, N. Appelman‐Dijkstra, 2014, Best practice & research. Clinical endocrinology & metabolism.

Use of bisphosphonates in the management of postmenopausal osteoporosis

S. Papapoulos, 2011, Annals of the New York Academy of Sciences.

Targeting sclerostin as potential treatment of osteoporosis

S. Papapoulos, 2011, Annals of the rheumatic diseases.

Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis

S. Papapoulos, P. Makras, 2008, Nature Clinical Practice Endocrinology &Metabolism.

Bisphosphonates: how do they work?

S. Papapoulos, 2008, Best practice & research. Clinical endocrinology & metabolism.

Ceramic hydroxyapatite implants for the release of bisphosphonate.

C. Löwik, S. Papapoulos, A. van den Hooff, 1994, Bone and mineral.

Regulation of parathyroid hormonelike protein production in cultured normal and malignant keratinocytes.

R. Offringa, M. Ponec, G. Hendy, 1992, The Journal of investigative dermatology.

Sclerostin and the regulation of bone formation: Effects in hip osteoarthritis and femoral neck fracture

M. Doube, J. Reeve, K. Poole, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Sclerostin: Current Knowledge and Future Perspectives

C. Löwik, S. Papapoulos, R. Van Bezooijen, 2010, Calcified Tissue International.

The Clinical Management of Osteoporosis

S. Papapoulos, 1999 .

Targeting the Wnt signaling pathway for the development of novel therapies for osteoporosis

M. Yavropoulou, S. Papapoulos, 2010, Expert review of endocrinology & metabolism.

Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/RANK ligand signaling?

C. Löwik, S. Papapoulos, R. Van Bezooijen, 2001, Bone.

Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice.

C. Cooper, R. Rizzoli, J. Kanis, 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Dissociation of Angiogenesis and Osteoclastogenesis During Endochondral Bone Formation in Neonatal Mice

A. Wetterwald, M. Cecchini, C. Löwik, 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Interleukin 17 synergises with tumour necrosis factor α to induce cartilage destruction in vitro

C. Löwik, S. Papapoulos, R. Van Bezooijen, 2002 .

A New Approach to the Development of Assessment Guidelines for Osteoporosis

S. Papapoulos, A. Silman, O. Johnell, 2002, Osteoporosis International.

Determinants of bone strength and clinical practice; effects of bisphosphonates

S. Papapoulos, 2007 .

Ovariectomy and orchidectomy induce a transient increase in the osteoclastogenic potential of bone marrow cells in the mouse.

C. Löwik, S. Papapoulos, A. Ederveen, 1997, Bone.

The flare in serum alkaline phosphatase activity after orchiectomy: a valuable negative prognostic index for progression-free survival in prostatic carcinoma.

A. Zwinderman, G. L. À. Lycklama à Nijeholt, R. Pelger, 1996, The Journal of urology.

Pharmacokinetics/Pharmacodynamics of Bisphosphonates

S. Cremers, S. Papapoulos, G. Pillai, 2005, Clinical pharmacokinetics.

Glucocorticoids are not always deleterious for bone

S. Papapoulos, N. Hamdy, A. V. van Lierop, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(12):6392–6395 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2005-1235 Bone Mineral Density in Sclerosteosis; Affected Individuals and Gene Carriers

P. Beighton, C. Löwik, S. Papapoulos, 2022 .

Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.

E. Pieterman, C. Löwik, S. Papapoulos, 1999, Biochemical and biophysical research communications.

Plasma nitrate+nitrite levels are regulated by ovarian steroids but do not correlate with trabecular bone mineral density in rats.

C. Löwik, I. Que, S. Papapoulos, 1998, The Journal of endocrinology.

CLEARANCE OF EXOGENOUS PARATHYROID HORMONE IN NORMAL AND URAEMIC MAN

G. Hendy, S. Papapoulos, J. O'riordan, 1977, Clinical endocrinology.

Identification of a retinoic acid-inducible element in the murine PTH/PTHrP (parathyroid hormone/parathyroid hormone-related peptide) receptor gene.

B. Lanske, L. Defize, M. Karperien, 1999, Molecular endocrinology.

Van Buchem disease: Clinical, biochemical, and densitometric features of patients and disease carriers

E. Bakker, F. Dikkers, M. V. van Egmond, 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Sclerostin deficiency in humans.

S. Papapoulos, N. Appelman-Dijkstra, A. V. van Lierop, 2017, Bone.

From disease to treatment: from rare skeletal disorders to treatments for osteoporosis

S. Papapoulos, N. Appelman-Dijkstra, N. Appelman‐Dijkstra, 2016, Endocrine.

Sclerostin Inhibition in the Management of Osteoporosis

S. Papapoulos, N. Appelman-Dijkstra, N. Appelman‐Dijkstra, 2016, Calcified Tissue International.

Circulating Sclerostin in Bone Sclerosing Disorders

S. Papapoulos, A. V. Lierop, 2016 .

Best Practice & Research Clinical Endocrinology & Metabolism

S. Papapoulos, N. Appelman-Dijkstra, N. Appelman‐Dijkstra, 2014 .

Inhibition of sclerostin in the management of osteoporosis: results of a phase 2 clinical trial meet expectations.

S. Papapoulos, 2014, BoneKEy reports.

Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women.

R. Rizzoli, T. Chevalley, S. Ferrari, 2013, The Journal of clinical endocrinology and metabolism.

Sclerostin in Mineralized Matrices and van Buchem Disease

P. Hogendoorn, W. Hul, C. Löwik, 2009, Journal of dental research.

Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls.

J. Witteveen, S. Papapoulos, N. Hamdy, 2010, European journal of endocrinology.

Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover

N. Loveridge, S. Papapoulos, J. Power, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

A rare cause of facial nerve palsy in children: hyperostosis corticalis generalisata (Van Buchem disease). Three new pediatric cases and a literature review.

O. Brouwer, F. Dikkers, M. V. van Egmond, 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

Implications for Fracture Healing of Current and New Osteoporosis Treatments: An ESCEO Consensus Paper

J. Goldhahn, J. Reginster, R. Rizzoli, 2012, Calcified Tissue International.

END-ORGAN RESISTANCE TO 1,25-DIHYDROXYCHOLECALCIFEROL

T. Clemens, U. Liberman, S. Papapoulos, 1980, The Lancet.

Chapter 4 Interference with the Microenvironment Support Impairs the De Novo Formation of Bone Metastasis In Vivo

A. Wetterwald, M. Cecchini, C. Löwik, 2009 .

The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates.

S. Papapoulos, N. Hamdy, 2001, Seminars in nuclear medicine.

Bisphosphonate Therapy in Children with Secondary Osteoporosis

S. Papapoulos, 2011, Hormone Research in Paediatrics.

Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease.

U. Liberman, K. Katz, R. Zaizov, 1994, Pediatrics.

Bisphosphonates for Postmenopausal Osteoporosis

A. Giusti, S. Papapoulos, 2018, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism.

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies

J. Reginster, A. Chines, E. Lewiecki, 2018, Osteoporosis International.

Long-Term Efficacy and Safety of Treatments for Osteoporosis

S. Papapoulos, 2016 .

The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.

J. Bilezikian, L. Fitzpatrick, D. Gordon, 2011, The Journal of clinical endocrinology and metabolism.

Treatment of Male Osteoporosis with Bisphosphonates

A. Giusti, S. Papapoulos, 2010 .

Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate

S. Papapoulos, R. Schimmer, 2007, Postgraduate Medical Journal.

Long-term therapy of osteoporosis with bisphosphonates: Evidence and implications for daily practice

S. Papapoulos, 2005 .

Who will benefit from antiresorptive treatment (bisphosphonates)?

S. Papapoulos, 2005, Best practice & research. Clinical rheumatology.

Daily Oral Pamidronate in Women and Men With Osteoporosis: A 3‐Year Randomized Placebo‐Controlled Clinical Trial With a 2‐Year Open Extension

A. Zwinderman, P. Lips, E. McCloskey, 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Yearly bisphosphonate infusions for the management of osteoporosis

S. Papapoulos, 2002 .

Chapter 72 – Bisphosphonates in the Management of Postmenopausal Osteoporosis

S. Papapoulos, 2001 .

A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis

S. Cremers, J. den Hartigh, S. Papapoulos, 2002, European Journal of Clinical Pharmacology.

CHAPTER 44 – Bisphosphonates

S. Papapoulos, 1999 .

Pharmacological management of osteoporosis

S. Papapoulos, 1998, Aging.

Long‐Term Effects of Bisphosphonates on the Growing Skeleton: Studies of Young Patients with Severe Osteoporosis

S. Papapoulos, C. Brumsen, Neveen A. T. Hamdy, 1997, Medicine.

Dual Photon Absorptiometry for Bone Mineral Measurements Using a Gamma Camera

R. Valkema, E. Pauwels, J. Camps, 1994, Acta radiologica.

Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines.

R. Rizzoli, R. Eastell, P. Delmas, 1999, Clinical therapeutics.

Palliative management of hormone refractory prostate cancer metastatic to the skeleton: comparative efficacy of 89 Strontium and the bisphosphonate olpadronate.

A. H. Zwinderman, R. Pelger, S. Papapoulos, 2006 .

Bone: Romosozumab — getting there but not quite yet

S. Papapoulos, 2016, Nature Reviews Endocrinology.

Osteoporosis: An Overview

P. Miller, M. McClung, S. Papapoulos, 2018 .

The role of bisphosphonates in the prevention and treatment of osteoporosis.

S. Papapoulos, 1993, The American journal of medicine.

Bisphosphonates in osteoporosis?

R. Valkema, C. Löwik, S. Papapoulos, 2005, Osteoporosis International.

Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion

S. Papapoulos, J. O. Landman, J. Landman, 1995, Osteoporosis International.

The use of bisphosphonates in the treatment of osteoporosis.

R. Valkema, E. Pauwels, C. Löwik, 1992, Bone.

Bone material strength index as measured by in vivo impact microindentation is normal in subjects with high-energy trauma fractures

I. Schipper, S. Papapoulos, N. Appelman-Dijkstra, 2022, Osteoporosis International.

Bone resorption and renal calcium reabsorption in renal cell carcinoma‐bearing mice: the effects of bisphosphonate

K. Kurth, D. Schamhart, C. Löwik, 2007, BJU international.

Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis

S. Papapoulos, N. Appelman-Dijkstra, N. Appelman‐Dijkstra, 2015, Drugs.

Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate

M. Yavropoulou, S. Papapoulos, N. Hamdy, 2013, Osteoporosis International.

The Role of Geranylgeranylation in Bone Resorption and Its Suppression by Bisphosphonates in Fetal Bone Explants In Vitro: A Clue to the Mechanism of Action of Nitrogen‐Containing Bisphosphonates

C. Löwik, G. van der Pluijm, S. Papapoulos, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Spine radiographs to improve the identification of women at high risk for fractures

P. Geusens, W. Lems, J. C. Netelenbos, 2009, Osteoporosis International.

Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years.

N. Watts, N. Binkley, M. McClung, 2019, The Journal of clinical endocrinology and metabolism.

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

J. Adachi, S. Ferrari, Andrea T Wang, 2017, BMC Musculoskeletal Disorders.

Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension

Jacques P. Brown, N. Watts, E. Lewiecki, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Oestrogenic Compounds Modulate Cytokine‐induced Nitric Oxide Production in Mouse Osteoblast‐like Cells

S. Papapoulos, C. Lowik, C. Bent, 1999, The Journal of pharmacy and pharmacology.

Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn’s disease

J. Hartigh, S. Cremers, S. Papapoulos, 2005, Osteoporosis International.

A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men.

P. Kluin, P. Kluin, S. Papapoulos, 2002, Bone.

SOST/Sclerostin: An Osteocyte-Derived Inhibitor of Bone Formation that Antagonizes Canonical Wnt Signaling

C. Löwik, S. Papapoulos, N. Hamdy, 2008 .

Precision of dual photon absorptiometry measurements: comparison of three different methods of selection of the region of interest

R. Valkema, E. Pauwels, J. Camps, 2004, European Journal of Nuclear Medicine.

Bisphosphonate actions: physical chemistry revisited.

S. Papapoulos, 2006, Bone.

The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study

E. McCloskey, B. Cortet, S. Papapoulos, 2020, Osteoporosis International.

Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.

S. Papapoulos, M. Frölich, 1996, The Journal of clinical endocrinology and metabolism.

Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD.

R. Valkema, E. Pauwels, S. Papapoulos, 1989, Bone and mineral.

Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies.

A. Giusti, S. Papapoulos, N. Hamdy, 2010, Bone.

Bilateral Fractures of the Femur Diaphysis in a Patient With Rheumatoid Arthritis on Long‐Term Treatment With Alendronate: Clues to the Mechanism of Increased Bone Fragility

P. Chavassieux, G. Boivin, S. Papapoulos, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Palliative pamidronate treatment in patients with bone metastases from breast cancer.

J. Hermans, H. Kroon, G. Blijham, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of experimental conditions on the release of 45calcium from prelabeled fetal mouse long bones.

C. Löwik, S. Papapoulos, E. V. van Beek, 1995, Bone.

Skeletal Retention of Bisphosphonate (Pamidronate) and Its Relation to the Rate of Bone Resorption in Patients With Breast Cancer and Bone Metastases

S. Cremers, C. Seynaeve, L. van Zuylen, 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Management of malignancy-associated hypercalcemia

S. Papapoulos, N. Hamdy, 2002 .

Crystal agglomeration is a major element in calcium oxalate urinary stone formation.

D. Kok, S. Papapoulos, O. Bijvoet, 1990, Kidney international.

The majority of the genetic risk for Paget’s disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes

P. Geusens, S. Boonen, E. Fransen, 2010, Human Genetics.

Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton

A. Zwinderman, J. Arndt, G. L. À. Lycklama à Nijeholt, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

Paget's Disease of Bone in The Netherlands: A Population‐Based Radiological and Biochemical Survey—The Rotterdam Study

A. Hofman, C. Cooper, H. Pols, 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effect of renal function on renal responsiveness to parathyroid hormone in primary hyperparathyroidism and chronic renal failure

G. Hendy, S. Papapoulos, J. O'riordan, 1985, European journal of clinical investigation.

Catabolic and anabolic signals in bone: therapeutic implications

S. Papapoulos, 2001, Current opinion in clinical nutrition and metabolic care.

Interleukin‐17: A New Bone Acting Cytokine In Vitro

C. Löwik, S. Papapoulos, R. Van Bezooijen, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Two distinct effects of recombinant human tumor necrosis factor-alpha on osteoclast development and subsequent resorption of mineralized matrix.

C. Löwik, G. van der Pluijm, G. Pluijm, 1991, Endocrinology.

Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton

G. van der Pluijm, S. Papapoulos, N. Hamdy, 2000, Cancer.

Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long‐Term Odanacatib Fracture Trial

M. Bouxsein, D. Dempster, Toshitaka Nakamura, 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Erratum: Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research (Journal of Bone and Mineral Research (2010) 25 (2267-2294))

T. Brown, P. Geusens, H. Genant, 2011 .

Investigative Urology: Hypercalcemia and Cosecretion of Interleukin-6 and Parathyroid Hormone Related Peptide by a Human Renal Cell Carcinoma Implanted Into Nude Mice

K. Kurth, D. Schamhart, P. Vos, 1995 .

Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in Europe

E. McCloskey, B. Cortet, S. Papapoulos, 2022, Archives of Osteoporosis.

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism

D. Bauer, T. Clemens, J. Bilezikian, 2009 .

Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management.

G. L. À. Lycklama à Nijeholt, R. Pelger, S. Papapoulos, 2005, Bone.

Calcium homeostasis in the fetal pig.

S. Papapoulos, J. O'riordan, A. Care, 1982, Journal of developmental physiology.

Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus.

J. Romijn, J. A. Smit, M. Diamant, 2012, European journal of endocrinology.

1α‐HYDROXYVITAMIN D3 IN THE LONG‐TERM MANAGEMENT OF H YPOP A R ATH Y ROIDISM AND PSEUDOHYPOPARATHYROIDISM

S. Papapoulos, J. O'riordan, I. Lewin, 1977 .

Integrins and osteoclastic resorption in three bone organ cultures: Differential sensitivity to synthetic arg‐gly‐asp peptides during osteoclast formation

C. Löwik, G. van der Pluijm, S. Papapoulos, 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The Prevalence of Low Bone Mineral Density in Dutch Perimenopausal Women: The Eindhoven Perimenopausal Osteoporosis Study

H. Pols, V. Pop, A. Zwinderman, 1998, Osteoporosis International.

Familial Paget's disease of bone: Long-term follow-up of unaffected relatives with and without Sequestosome 1 mutations.

W. Van Hul, S. Papapoulos, F. Smit, 2019, Bone.

Familial Paget's disease in The Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations.

A. Zwinderman, M. Karperien, S. Papapoulos, 2004, Arthritis and rheumatism.

IL‐1α, IL‐1β, IL‐6, and TNF‐α Steady‐State mRNA Levels Analyzed by Reverse Transcription‐Competitive PCR in Bone Marrow of Gonadectomized Mice

C. Löwik, S. Papapoulos, R. Van Bezooijen, 1998 .

Effect of Angiogenic and Antiangiogenic Compounds on the Outgrowth of Capillary Structures from Fetal Mouse Bone Explants

C. Löwik, G. Pluijm, S. Papapoulos, 2001, Laboratory Investigation.

1, 25-DIHYDROXYCHOLECALCIFEROL IN THE PATHOGENESIS OF THE HYPERCALCÆMIA OF SARCOIDOSIS

T. Clemens, S. Papapoulos, L. Fraher, 1979, The Lancet.

MEASUREMENT OF 1,25‐DIHYDROXYCHOLECALCIFEROL IN MAN BY RADIOIMMUNOASSAY

G. Hendy, S. Papapoulos, L. Fraher, 1979, Clinical endocrinology.

First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function

D. Adriaensen, T. Mueller, J. Timmermans, 2010, Human mutation.

Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate)

G. Massa, S. Papapoulos, P. Maaswinkel-Mooy, 1997, European Journal of Pediatrics.

Epi- and metaphyseal changes in children caused by administration of bisphosphonates.

E. L. van Persijn van Meerten, H. Kroon, S. Papapoulos, 1992, Radiology.

Nasal Levels of Antimicrobial Peptides in Allergic Asthma Patients and Healthy Controls: Differences and Effect of a Short 1,25(OH)2 Vitamin D3 Treatment

K. Rabe, S. le Cessie, S. Middeldorp, 2015, PloS one.

Inhibition of intravacuolar acidification by antisense RNA decreases osteoclast differentiation and bone resorption in vitro.

C. Löwik, H. Väänänen, S. Papapoulos, 1999, Journal of cell science.

SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development

C. Mummery, M. DeRuiter, P. Hogendoorn, 2007, Developmental dynamics : an official publication of the American Association of Anatomists.

Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.

C. Löwik, S. Papapoulos, E. V. van Beek, 2002, Bone.

Osteoclast formation together with interleukin-6 production in mouse long bones is increased by insulin-like growth factor-I.

C. Löwik, S. Papapoulos, L. Schot, 1992, The Journal of endocrinology.

Pamidronate: A model compound of the pharmacology of nitrogen-containing bisphosphonates; A Leiden historical perspective.

S. Papapoulos, 2020, Bone.

Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).

S. Papapoulos, A. Moolenaar, O. Bijvoet, 1987, British medical journal.

Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis.

S. Papapoulos, K. Hoekman, O. Bijvoet, 1985, The Journal of clinical endocrinology and metabolism.

Paget's disease of bone: clinical, pathogenetic and therapeutic aspects.

S. Papapoulos, 1997, Bailliere's clinical endocrinology and metabolism.

Improved treatment of paget's disease with dimethylaminohydroxypropylidene bisphosphonate

A. Zwinderman, S. Papapoulos, O. Bijvoet, 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study.

F. Breedveld, S. Papapoulos, B. Dijkmans, 1994, The Journal of rheumatology.

Founder Effect in Different European Countries for the Recurrent P392L SQSTM1 Mutation in Paget’s Disease of Bone

Jean-Pierre Devogelaer, Rene Westhovens, Marcel Karperien, 2008, Calcified Tissue International.

Paget's disease of bone.

S. Papapoulos, N. Appelman-Dijkstra, N. Appelman‐Dijkstra, 2001, Best practice & research. Clinical endocrinology & metabolism.

Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget's disease of bone

P. Geusens, S. Boonen, S. Ralston, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

In vitro and in vivo endochondral bone formation models allow identification of anti-angiogenic compounds.

C. Löwik, A. Baxter, G. van der Pluijm, 2003, The American journal of pathology.

Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis.

L. Aarden, C. Löwik, G. van der Pluijm, 1989, Biochemical and biophysical research communications.

Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype.

E. Brown, M. Brandi, G. Hendy, 1994, The Journal of clinical investigation.

Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism

J. Seidman, E. Brown, C. Seidman, 1995, Pediatric Nephrology.

Strategies of treatment of Paget's disease with bisphosphonates.

S. Papapoulos, 1994, Seminars in arthritis and rheumatism.

Effect of vitamin D treatment on antimicrobial peptides in asthma patients and healthy controls

S. Cessie, K. Rabe, S. Middeldorp, 2011 .

The effects of dietary excesses in animal protein and in sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men.

D. Kok, S. Papapoulos, C. J. Doorenbos, 1990, The Journal of clinical endocrinology and metabolism.

Quantification of adherent and nonadherent cells cultured in 96-well plates using the supravital stain neutral red.

C. Löwik, G. van der Pluijm, S. Papapoulos, 1993, Analytical biochemistry.

Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro.

C. Löwik, S. Papapoulos, R. Van Bezooijen, 2002, Annals of the rheumatic diseases.

Sclerostin: current knowledge and future perspectives 2

S. Papapoulos, C. Löwik, M. Moester, 2014 .

SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.

P. ten Dijke, C. Löwik, S. Papapoulos, 2005, Cytokine & growth factor reviews.

Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX gene.

S. Kant, S. Papapoulos, P. Makras, 2008, The Journal of clinical endocrinology and metabolism.

The effect of renal function on changes in circulating concentrations of 1,25-dihydroxycholecalciferol after an oral dose.

J. Winer, T. Clemens, S. Papapoulos, 1982, Clinical science.

Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: the role of the retinoic acid receptor.

M. Karperien, C. Löwik, S. Papapoulos, 2006, Bone.

The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation.

S. Polyzos, M. Yavropoulou, S. Papapoulos, 2021, The Journal of clinical endocrinology and metabolism.

Regulation of the production of plasminogen activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells.

J. Verheijen, C. Löwik, S. Papapoulos, 1991, Bone and mineral.

Evidence for extrarenal metabolism of 25-hydroxyvitamin D3 in man.

S. Adami, S. Papapoulos, J. O'riordan, 1986, Clinical science.

Renal responsiveness to synthetic human parathyroid hormone 1–38 in healthy subjects

D. Roelen, S. Papapoulos, M. Frölich, 1989, European journal of clinical investigation.

CONTROL OF SECRETION OF PARATHYROID HORMONE IN SECONDARY HYPERPARATHYROIDISM

S. Adami, N. Muirhead, S. Papapoulos, 1982, Clinical endocrinology.

Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?

R. Eastell, R. Russell, S. Papapoulos, 1993, Bone and mineral.

Measurement of circulating sclerostin

S. Papapoulos, A. V. Lierop, 2013 .

Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover.

R. Rizzoli, M. Yavropoulou, S. Papapoulos, 2012, Bone.

The Role of Sclerostin in the Pathophysiology of Sclerosing Bone Dysplasias

C. Löwik, S. Papapoulos, N. Hamdy, 2012, Clinical Reviews in Bone and Mineral Metabolism.

Modulation of calcium oxalate monohydrate crystallization kinetics in vitro.

D. Kok, S. Papapoulos, O. Bijvoet, 1988, Kidney international.

Determination of circulating 25,26-dihydroxycholecalciferol in man by radioimmunoassay.

T. Clemens, S. Papapoulos, J. O'riordan, 1980, Clinical science.

Increased Bone Resorption during Lactation in Pycnodysostosis

I. Jansen, S. Papapoulos, N. Bravenboer, 2021, International journal of molecular sciences.

Reversible resistance to the renal action of parathyroid hormone in human vitamin D deficiency.

G. Hendy, S. Papapoulos, J. O'riordan, 1982, Clinical science.

Regulation of calcium absorption by 1,25,dihydroxy-vitamin D—Studies of the effects of a bisphosphonate treatment

T. Clemens, S. Adami, S. Papapoulos, 1982, Calcified Tissue International.

Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.

S. Papapoulos, 2000, Annales de medecine interne.

Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.

C. Löwik, S. Papapoulos, R. Van Bezooijen, 2005, Journal of endocrinological investigation.

Bone diseases: Bisphosphonates in osteoporosis—beyond 5 years

S. Papapoulos, 2013, Nature Reviews Rheumatology.

Denosumab for the treatment of primary pediatric osteoporosis

S. Polyzos, S. Papapoulos, V. Guarnieri, 2021, Osteoporosis International.

The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.

S. Polyzos, S. Papapoulos, P. Makras, 2020, Bone.

Optimization of follow-up measurements of bone mass.

A. Zwinderman, E. Pauwels, S. Papapoulos, 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates.

C. Löwik, S. Papapoulos, F. Ebetino, 2003, Bone.

Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism?

S. Papapoulos, N. Hamdy, A. V. van Lierop, 2011, European journal of endocrinology.

Osteoporosis and Bone Marrow Mastocytosis: Dissociation of Skeletal Responses and Mast Cell Activity During Long‐Term Bisphosphonate Therapy

S. Papapoulos, N. Hamdy, C. Brumsen, 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Chronic acidosis with metabolic bone disease. Effect of alkali on bone morphology and vitamin D metabolism.

T. Clemens, J. Cunningham, P. Revell, 1982, The American journal of medicine.

Effect of Alkali on Bone Morphology and Vitamin D Metabolism

T. Clemens, J. Cunningham, P. Revell, 1982 .

Ectopic production of 1,25‐dihydroxyvitamin D by B‐cell lymphoma as a cause of hypercalcemia

F. Breedveld, H. Berg, P. Kluin, 1987, Cancer.

Differential regulation of plasminogen activation in normal keratinocytes and SCC-4 cells by fibroblasts.

P. Quax, M. Ponec, J. Verheijen, 1995, The Journal of investigative dermatology.

Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment.

S. Papapoulos, A. Mudde, O. Bijvoet, 1987, The Journal of clinical endocrinology and metabolism.

Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.

S. Polyzos, S. Papapoulos, P. Makras, 2012, Bone.

Impact microindentation measurements correlate with cortical bone material properties measured by Fourier transform infrared imaging in humans.

J. Zwerina, P. Chavassieux, E. Paschalis, 2020, Bone.

Impact Microindentation: Consistency of Serial Measurements and Alterations in Patients With Paget's Disease of the Tibia

S. Papapoulos, N. Hamdy, N. Appelman-Dijkstra, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Recovery of serum calcium concentrations following acute hypocalcemia in patients with osteoporosis on long-term oral therapy with the bisphosphonate pamidronate.

S. Papapoulos, N. Hamdy, M. Frölich, 1995, The Journal of clinical endocrinology and metabolism.

Immunoradiometric Assay for Intact Human Parathyroid Hormone: Characteristics, Clinical Application and Comparison with a Radio-Immunoassay

S. Papapoulos, M. Frölich, S. Walma, 1990, Annals of clinical biochemistry.

Bone metabolism in rheumatoid arthritis; relation to disease activity.

M. Westedt, F. Breedveld, S. Papapoulos, 1993, British journal of rheumatology.

EXCESSIVE CRYSTAL AGGLOMERATION WITH LOW CITRATE EXCRETION IN RECURRENT STONE-FORMERS

D. Kok, S. Papapoulos, O. Bijvoet, 1986, The Lancet.

Effects of Mutant Gene Dosage on Phenotype

J. Seidman, E. Brown, C. Seidman, 2016 .

HYPERPARATHYROIDISM IN CHRONIC RENAL FAILURE

G. Hendy, F. Marsh, S. Papapoulos, 1977, Clinical endocrinology.

A frame-shift mutation in the type I parathyroid hormone (PTH)/PTH-related peptide receptor causing Blomstrand lethal osteochondrodysplasia.

P. Nijweide, P. Nijweide, M. Karperien, 1999, The Journal of clinical endocrinology and metabolism.

Mutations in the human Ca(2+)-sensing-receptor gene that cause familial hypocalciuric hypercalcemia.

J. Seidman, E. Brown, M. Brandi, 1995, American journal of human genetics.

Denosumab in Patients with Fibrous Dysplasia Previously Treated with Bisphosphonates.

P. Dijkstra, M. Fiocco, S. Papapoulos, 2019, The Journal of clinical endocrinology and metabolism.

Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD.

S. Papapoulos, J. O'riordan, L. Fraher, 1986, Bone and mineral.

Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.

E. Pieterman, C. Löwik, S. Papapoulos, 1999, Biochemical and biophysical research communications.

The Role of Interleukin-6 in the Induction of Hypercalcemia in Renal Cell Carcinoma Transplanted into Nude Mice.

K. Kurth, D. Schamhart, S. Papapoulos, 1997, Endocrinology.

The role of interleukin-6 in the induction of hypercalcemia in renal cell carcinoma transplanted into nude mice Weissglas,

K. Kurth, D. Schamhart, C. Löwik, 1997 .

SAT0479 Early Findings from Prolia® Post-Marketing Safety Surveillance for Atypical Femoral Fracture, Osteonecrosis of the Jaw, Severe Symptomatic Hypocalcemia, and Anaphylaxis

N. Watts, C. Stehman-Breen, S. Papapoulos, 2014 .

Automated comparison of dual‐photon absorptiometric studies of the lumbar spine

E. Pauwels, S. Papapoulos, O. Bijvoet, 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bone fragility in patients affected by congenital diseases non skeletal in origin

M. Brandi, D. Pierroz, L. Masi, 2021, Orphanet Journal of Rare Diseases.

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

J. Reeve, C. Löwik, K. Poole, 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist

M. Karperien, B. Roelen, P. ten Dijke, 2004, The Journal of experimental medicine.

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.

D. Galas, S. Proll, P. Beighton, 2002, American journal of medical genetics.

Serum osteocalcin levels before and after 1,25 dihydroxy-vitamin D stimulation in a family with hypophosphatasia.

J. Macfarlane, S. Papapoulos, M. Frölich, 1991, Bone.

Marcel Karperien, M. Karperien, S. Papapoulos, 2022 .

Bone Histomorphometric Evaluation of Pamidronate Treatment in Clinically Manifest Osteoporosis

P. Lips, J. C. Netelenbos, S. Papapoulos, 1999, Osteoporosis International.

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.

J. Reginster, R. Rizzoli, D. Felsenberg, 2008, Bone.

Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group

C. Löwik, I. Que, S. Papapoulos, 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research

Thomas D Brown, Klaus Klaushofer, Jeffrey R Curtis, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

New insights into the role of vitamin D and calcium in osteoporosis management: an expert roundtable discussion

H. Bischoff-Ferrari, R. Bouillon, C. Roux, 2008 .

Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships.

C. Löwik, F. H. Ebetino, S. Papapoulos, 1998, Bone.

Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment.

A. Zwinderman, B. Dijkmans, K. Han, 1995, Arthritis and rheumatism.

Physicochemical considerations in the development and prevention of calcium oxalate urolithiasis.

D. Kok, S. Papapoulos, 1993, Bone and mineral.

Low inhibition of crystal agglomeration and citrate excretion in recurrent calcium oxalate stone formers.

D. Kok, S. Papapoulos, O. Bijvoet, 1987, Contributions to nephrology.

The effects of low and high molecular weight substances on citrate — induced changes of growht and agglomeration of calcium oxalate crystals

D. Kok, S. Papapoulos, O. Bijvoet, 1988 .

The Relationship Between Citrate and Calcium-Oxalate Crystal Agglomeration

D. Kok, I. Que, S. Papapoulos, 1989 .

A physicochemical explanation for the role of citrate in recurrent stone disease

D. Kok, S. Papapoulos, O. Bijvoet, 1987 .

Peroxisome Proliferator-activated Receptor γ (PPARγ) as a Molecular Target for the Soy Phytoestrogen Genistein*

J. Boutin, C. Löwik, V. Audinot, 2003, The Journal of Biological Chemistry.

Peroxisome proliferator-activated receptor gamma (PPARgamma ) as a molecular target for the soy phytoestrogen genistein.

J. Boutin, C. Löwik, V. Audinot, 2003, The Journal of biological chemistry.

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

C. Cooper, J. Reginster, R. Rizzoli, 2010, Osteoporosis International.

Composites of hydroxyapatite and bisphosphonate: properties and alveolar bone response

W. Kalk, S. Papapoulos, H. Denissen, 1995 .

Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem.

C. Löwik, G. Pluijm, S. Papapoulos, 2000, Cancer treatment reviews.

Inhibition of Cathepsin K for Treatment of Osteoporosis

S. Boonen, F. Claessens, D. Vanderschueren, 2012, Current Osteoporosis Reports.

STUDIES OF CIRCULATING PARATHYROID HORMONE IN MAN USING A HOMOLOGOUS AMINO‐TERMINAL SPECIFIC IMMUNORADIOMETRIC ASSAY

G. Hendy, S. Papapoulos, I. Lewin, 1980, Clinical endocrinology.

Pharmacology of bisphosphonates.

S. Cremers, S. Papapoulos, 2011, Bone.

Genome-wide association identifies three new susceptibility loci for Paget's disease of bone

F. Gianfrancesco, S. Ralston, M. Brandi, 2011, Nature Genetics.

Meeting report from the 24th annual meeting of the American society for bone and mineral research

D. Black, D. Vanderschueren, S. Ralston, 2002 .

Monitoring Metastatic Behavior of Human Tumor Cells in Mice with Species‐Specific Polymerase Chain Reaction: Elevated Expression of Angiogenesis and Bone Resorption Stimulators by Breast Cancer in Bone Metastases

H. Vloedgraven, C. Löwik, G. van der Pluijm, 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bone Morphogenetic Proteins Stimulate Angiogenesis through Osteoblast-Derived Vascular Endothelial Growth Factor A.

S. Papapoulos, Socrates E Papapoulos, Rutger L van Bezooijen, 2002, Endocrinology.

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.

H. Vloedgraven, G. van der Pluijm, G. Pluijm, 1996, The Journal of clinical investigation.

Management of Glucocorticoid-Induced Osteoporosis

C. Cooper, J. Reginster, R. Rizzoli, 2012, Calcified Tissue International.

Structural requirements for bisphosphonate actions in vitro

S. Papapoulos, E. V. van Beek, M van de Ruit, 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

International conference on biomedical aspects of aging research

R. A. Miller, L. Schneider, B. Hyman, 1998 .

Interpretation and use of FRAX in clinical practice

C. Cooper, R. Rizzoli, J. Kanis, 2011, Osteoporosis International.

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

J. Eisman, D. Dempster, Toshitaka Nakamura, 2014, Osteoporosis International.

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.

D. Kiel, M. Sabatine, J. Reginster, 2019, The lancet. Diabetes & endocrinology.

Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway

S. Papapoulos, N. Appelman-Dijkstra, N. Appelman‐Dijkstra, 2018, Nature Reviews Endocrinology.

Parathyroid venous sampling: anatomic considerations and results in 95 patients with primary hyperparathyroidism.

S. Papapoulos, J. O'riordan, B. Kendall, 1980, The British journal of radiology.

Facial dysmorphia, parathyroid and thymic dysfunction in the father of a newborn with the DiGeorge complex

S. Papapoulos, J. Kamp, A. Mudde, 1989, European Journal of Pediatrics.

Serum Dickkopf 1 levels in sclerostin deficiency.

S. Papapoulos, N. Hamdy, A. V. van Lierop, 2014, The Journal of clinical endocrinology and metabolism.

The effect of tissue type plasminogen activator (tPA) on osteoclastic resorption in embryonic mouse long bone explants: a possible role for the growth factor domain of tPA.

J. Verheijen, C. Löwik, S. Papapoulos, 1992, Bone and mineral.

New insights into the role of vitamin D and calcium in osteoporosis management: an expert roundtable discussion.

H. Bischoff-Ferrari, R. Bouillon, C. Roux, 2008, Current medical research and opinion.

Wnt but Not BMP Signaling Is Involved in the Inhibitory Action of Sclerostin on BMP‐Stimulated Bone Formation

H. Vrieling, M. Karperien, P. ten Dijke, 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Leukemia inhibitory factor inhibits osteoclastic resorption, growth, mineralization, and alkaline phosphatase activity in fetal mouse metacarpal bones in culture

P. Nijweide, C. Löwik, S. Papapoulos, 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

In vitro and Ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis

C. Löwik, S. Papapoulos, L. Schot, 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Malignancy‐associated hypercalcaemia: resolution of controversies over vitamin D metabolism by a pathophysiological approach to the syndrome

S. Papapoulos, N. Hamdy, D. Schweitzer, 1994, Clinical endocrinology.

Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research

T. Brown, P. Geusens, H. Genant, 2011 .

Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis.

B. Dijkmans, W. Lems, S. Cremers, 2004, The Journal of rheumatology.

arthritis . degradation after intravenous bisphosphonate ( pamidronate ) in rheumatoid Short term whole body retention in relation to rate of bone resorption and cartilage

B. Dijkmans, J. Hartigh, S. Cremers, 2004 .

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

J. Reginster, C. Roux, E. Franek, 2015, Osteoporosis International.

Interim Report and Recommendations of the World Health Organization Task-Force for Osteoporosis

Harry K. Genant, Paul D. Miller, Bess Dawson-Hughes, 1999, Osteoporosis International.

Medical treatment of hypercalcaemia

S. Papapoulos, P. Makras, 2009, Hormones.

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.

Jacques P. Brown, S. Cummings, J. Reginster, 2017, The lancet. Diabetes & endocrinology.

Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial

B. Mitlak, J. Bilezikian, P. Miller, 2019, Current medical research and opinion.

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

R. Rizzoli, B. Mitlak, J. Bilezikian, 2018, The Journal of clinical endocrinology and metabolism.

The role of 1,25‐dihydroxyvitamin D in the maintenance of hypercalcemia in a patient with an ovarian carcinoma producing parathyroid hormone‐related protein

S. Papapoulos, K. Hoekman, Y. I. Tjandra, 1991, Cancer.

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

Jacques P. Brown, S. Cummings, E. Vittinghoff, 2013, The Journal of clinical endocrinology and metabolism.

Bone material strength as measured by microindentation in vivo is decreased in patients with fragility fractures independently of bone mineral density.

S. Papapoulos, N. Hamdy, N. Appelman-Dijkstra, 2015, The Journal of clinical endocrinology and metabolism.

Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines.

R. Rizzoli, R. Eastell, P. Delmas, 1999, Clinical therapeutics.

Implications for Fracture Healing of Current and New Osteoporosis Treatments: An ESCEO Consensus Paper

J. Goldhahn, J. Reginster, R. Rizzoli, 2012, Calcified Tissue International.

Validation of a novel, rapid, high precision sclerostin assay not confounded by sclerostin fragments.

S. Khosla, M. Drake, S. Papapoulos, 2018, Bone.

Sclerostin: From bedside to bench, and back to bedside.

A. Robling, M. Drake, S. Papapoulos, 2017, Bone.

Control of bone formation by osteocytes? lessons from the rare skeletal disorders sclerosteosis and van Buchem disease

P. Dijke, C. Löwik, Peter ten Dijke, 2005 .

Targeting Bone Remodeling for the Treatment of Osteoporosis: Summary of the Proceedings of an ASBMR Workshop

R. Recker, S. Khosla, J. Bilezikian, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy.

A. Zwinderman, S. Cremers, S. Papapoulos, 2003, Bone.

Pharmacological management of Paget's disease of bone

S. Papapoulos, 2002 .

Use of a rat model for the simultaneous assessment of pharmacokinetic and pharmacodynamic aspects of bisphosphonate treatment: Application to the study of intravenous 14C‐labeled 1‐hydroxy‐3‐(1‐pyrrolidinyl)‐propylidene‐1,1‐bisphosphonate

S. Koopmans, S. Papapoulos, L. van der Wee‐Pals, 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Modulation of tumour-induced bone resorption by bisphosphonates

S. Papapoulos, A. Holten-Verzantvoort, 1992, The Journal of Steroid Biochemistry and Molecular Biology.

Disodium 1‐hydroxy‐3‐(1‐pyrrolidinyl)‐propylidene‐1,1‐bisphosphonate (EB‐1053) is a potent inhibitor of bone resorption in vitro and in vivo

L. Binderup, C. Löwik, G. van der Pluijm, 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice.

K. Kurth, D. Schamhart, P. Vos, 1995, The Journal of urology.

Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.

S. Vukicevic, A. Cleton-Jansen, R. Lidereau, 2007, Cancer research.

BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo.

Antoinette Wetterwald, Ruth Schwaninger, S. Vukicevic, 2007, The American journal of pathology.

Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.

M. Yavropoulou, F. Papadopoulou, S. Papapoulos, 2017, European journal of endocrinology.

Sclerostin Inhibition in the Management of Osteoporosis

S. Papapoulos, N. Appelman-Dijkstra, N. Appelman‐Dijkstra, 2016, Calcified Tissue International.

Prolonged bisphosphonate release after treatment in children.

S. Cremers, S. Papapoulos, 2007, The New England journal of medicine.

Bone material strength index as measured by impact microindentation is low in patients with fractures irrespective of fracture site

S. Papapoulos, N. Appelman-Dijkstra, N. Hamdy, 2017, Osteoporosis International.

Chapter 2 Prognostic Significance of Periodic Acid-Schiff-positive Patterns in Primary Breast Cancer and its Lymph Node Metastases

V. Smit, C. Löwik, J. Buijs, 2009 .

Prognostic Significance of Periodic Acid-Schiff-Positive Patterns in Primary Breast Cancer and its Lymph Node Metastases

V. Smit, C. Löwik, G. van der Pluijm, 2004, Breast Cancer Research and Treatment.

Plasma adenosine 3′, 5′-cyclic monophosphate: Dose-response to injected bovine parathyroid hormone in man

G. Hendy, S. Papapoulos, J. O'riordan, 1976, Calcified Tissue Research.

Avascular necrosis of bone after renal transplantation: role of parathyroid hormone and vitamin D.

S. Papapoulos, J. O'riordan, B. Hulme, 1978, British medical journal.

Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components.

H. Vloedgraven, W. Grzesik, P. Robey, 1997, Laboratory investigation; a journal of technical methods and pathology.

IL-1alpha, IL-1beta, IL-6, and TNF-alpha steady-state mRNA levels analyzed by reverse transcription-competitive PCR in bone marrow of gonadectomized mice.

C. Löwik, S. Papapoulos, R. Van Bezooijen, 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women

M. Hochberg, S. Quandt, U. Liberman, 2005, Osteoporosis International.

Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial.

B. Dijkmans, M. Westedt, F. Breedveld, 1996, Arthritis and rheumatism.

Development of homologous immunological assays for human parathyroid hormone.

G. Hendy, S. Papapoulos, J. O'riordan, 1980, The Journal of endocrinology.

Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton.

A. Zwinderman, R. Pelger, S. Papapoulos, 1998, Bone.

The reproducibility of single photon absorptiometry in a clinical setting

R. Valkema, E. Pauwels, S. Papapoulos, 2004, European Journal of Nuclear Medicine.

Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in Europe

E. McCloskey, B. Cortet, S. Papapoulos, 2022, Archives of Osteoporosis.

Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

J. Eisman, D. Dempster, S. Greenspan, 2015, Osteoporosis International.

Prevention of incident fractures in patients with prevalent fragility fractures: Current and future approaches.

S. Papapoulos, N. Appelman-Dijkstra, N. Appelman‐Dijkstra, 2013, Best practice & research. Clinical rheumatology.

Clinical risk factors as predictors of postmenopausal osteoporosis in general practice.

A. Zwinderman, S. Papapoulos, G. D. de Bock, 2001, The British journal of general practice : the journal of the Royal College of General Practitioners.

6 Can we prevent fractures

T. O’Neill, S. Papapoulos, 1997 .

Goal-directed treatment of osteoporosis in Europe

J. Reginster, R. Rizzoli, J. Kaufman, 2014, Osteoporosis International.

METABOLITES OF VITAMIN D IN HUMAN VITAMIN-D DEFICIENCY: EFFECT OF VITAMIN D3 OR 1,25-DIHYDROXYCHOLECALCIFEROL

T. Clemens, S. Papapoulos, J. O'riordan, 1980, The Lancet.

Exposure of KS483 Cells to Estrogen Enhances Osteogenesis and Inhibits Adipogenesis

M. Karperien, C. Löwik, S. Papapoulos, 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Is a single infusion of zoledronic acid superior to risedronate for the treatment of Paget's disease?

S. Papapoulos, 2006, Nature Clinical Practice Endocrinology &Metabolism.

Relationships Between Pharmacokinetics and Rate of Bone Turnover After Intravenous Bisphosphonate (Olpadronate) in Patients With Paget's Disease of Bone

S. Cremers, J. den Hartigh, S. Papapoulos, 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer

A. Zwinderman, J. Arndt, R. Pelger, 2004, European Journal of Nuclear Medicine and Molecular Imaging.

Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate.

E. Pauwels, S. Papapoulos, N. Hamdy, 1995, The Journal of clinical endocrinology and metabolism.

Technical note: Recommendations for a standard procedure to assess cortical bone at the tissue-level in vivo using impact microindentation

A. Diez-Perez, M.L. Bouxsein, E.F. Eriksen, 2016, Bone reports.

Modulation of calcium oxalate monohydrate crystallization kinetics by urine of preterm neonates.

R. Brand, D. Kok, I. Que, 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Interleukin‐6 and the acute phase response during treatment of patients with paget's disease with the nitrogen‐containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate

C. Löwik, G. van der Pluijm, S. Papapoulos, 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment.

M. den Heijer, A. Hermus, S. Papapoulos, 2012, The Journal of clinical endocrinology and metabolism.

Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.

A. Zwinderman, S. Papapoulos, P. Makras, 2009, Bone.

Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐Year Clinical Trial

S. Polyzos, S. Papapoulos, P. Makras, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data

C. Cooper, J. Reginster, S. Silverman, 2009, Osteoporosis International.

Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption.

P. Nibbering, C. Löwik, S. Papapoulos, 1994, The Journal of clinical investigation.

Five Years of Cenosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension

Jacques P. Brown, S. Cummings, E. Vittinghoff, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials

E. Lewiecki, D. Mehta, S. Papapoulos, 2010, International journal of clinical practice.

Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.

D. Felsenberg, G. Armbrecht, S. Papapoulos, 2005, Bone.

Automatic region of interest determination in dual photon absorptiometry of the lumbar spine.

A M Vossepoel, R. Valkema, A. Vossepoel, 1991, IEEE transactions on medical imaging.

Modulation of PTH‐stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants

G. van der Pluijm, S. Papapoulos, M. J. Alblas, 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial

Zanchetta, D. Kiel, J. Reginster, 2015 .

Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials

E. Barrett-Connor, U. Liberman, A. Santora, 2011, Osteoporosis International.

Limited precision of lumbar spine dual-photon absorptiometry by variations in the soft-tissue background.

A. Zwinderman, R. Valkema, E. Pauwels, 1990, Journal of Nuclear Medicine.

Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.

E. Oldfield, Yongcheng Song, D. González-Pacanowska, 2005, Journal of medicinal chemistry.

Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.

C. Löwik, G. van der Pluijm, J. Buijs, 2009, Bone.

Usefulness of Armspan and Height Comparison in Detecting Vertebral Deformities in Women

S. Papapoulos, M. Springer, H. Petri, 1999, Osteoporosis International.

Five-year denosumab treatment of postmenopausalwomen with osteoporosis: results of the first twoyears of the freedom trial extension.

S. Cummings, J. Reginster, A. Grauer, 2011 .

Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the freedom extension

J. Reginster, C. Roux, E. Franek, 2014 .

Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice.

C. Löwik, S. Papapoulos, E. V. van Beek, 1997, Bone.

Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?

J. Hermans, G. Blijham, S. Papapoulos, 1996, European journal of cancer.

Zoledronate decreases CTLA-4 in vivo and in vitro independently of its action on bone resorption.

A. Giusti, S. Papapoulos, G. Bianchi, 2020, Bone.

Long-term experience of alfacalcidol in renal osteodystrophy.

F. Marsh, S. Papapoulos, A. Brownjohn, 1982, The Quarterly journal of medicine.

Chapter 6 Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer

S. Vukicevic, A. Cleton-Jansen, R. Lidereau, 2009 .

Ten years of Denosumab (DMAB) treatment in postmenopausal women with osteoporosis. Results from the FREEDOM Extension trial.

Jacques P. Brown, S. Cummings, J. Reginster, 2016 .

Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat

Thomas Pfister, F. Bauss, T. Pfister, 2008, Journal of Bone and Mineral Metabolism.

Treatments of osteoporosis increase bone material strength index in patients with low bone mass

S. Papapoulos, E. Winter, N. Appelman-Dijkstra, 2020, Osteoporosis International.

The Relationship Between Phalangeal Bone Density and Vertebral Deformities

S. Papapoulos, M. Springer, F. Vismans, 2000, Calcified Tissue International.

Clear osteolytic metastases and hypercalcaemia: an unusual presentation of hormone refractory prostate cancer.

M. Karperien, R. Pelger, S. Papapoulos, 2006 .

Paget's disease with osteolytic lesions: combining medical and surgical treatments.

S. Papapoulos, C. Brumsen, R. Bloem, 1992, The Netherlands journal of medicine.

Parathyroid hormone related protein and interleukin-6 mRNA expression in larynx and renal cell carcinomas from normocalcaemic and hypercalcaemic patients.

R. J. Baatenburg de Jong, C. Löwik, J. V. van Krieken, 1995, Journal of clinical pathology.

Studies of hypoparathyroidism and pseudohypoparathyroidism.

G. Hendy, S. Papapoulos, J. O'riordan, 1978, The Quarterly journal of medicine.

Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.

S. Adami, N. Muirhead, S. Papapoulos, 1980, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation.

M. Karperien, C. Löwik, S. Papapoulos, 2000, Endocrinology.

Inhibitory effect of 25,26-dihydroxycholecalciferol on the rate of secretion of parathyroid hormone in goats.

S. Papapoulos, J. O'riordan, A. Care, 1978, The Journal of endocrinology.

Controversial issues in climacteric medicine IV Postmenopausal osteoporosis: therapeutic options

C. Christiansen, C. Campagnoli, J. Kanis, 2005 .

A CARBOXY‐TERMINAL SPECIFIC ASSAY FOR HUMAN PARATHYROID HORMONE

G. Hendy, S. Adami, S. Papapoulos, 1981, Clinical endocrinology.

Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.

S. Papapoulos, R. Schimmer, 2007, Annals of the Rheumatic Diseases.

Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV‐positive persons version 9.0

S. McCormack, A. Mocroft, O. Kirk, 2018, HIV medicine.

Investigative Urology: Hypercalcemia and Cosecretion of Interleukin-6 and Parathyroid Hormone Related Peptide by a Human Renal Cell Carcinoma Implanted Into Nude Mice

K. Kurth, D. Schamhart, S. Papapoulos, 1995 .

Acquired Resistance to Bisphosphonates in Paget's Disease of Bone

A. Zwinderman, S. Papapoulos, Aeilko H Zwinderman, 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

1-alpha-hydroxycholecalciferol for renal osteodystrophy.

F. Marsh, S. Papapoulos, J. O'riordan, 1977, British medical journal.

Best Practice & Research Clinical Endocrinology & Metabolism

J. Kaufman, B. Lapauw, S. Goemaere, 2014 .

New Bone-Forming Agents

S. Papapoulos, 2018, Pocket Reference to Osteoporosis.

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism

J. Bilezikian, G. David Roodman, S. Papapoulos, 2013 .

Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis

S. Papapoulos, 2015, Nature Reviews Endocrinology.

Prevention of incident fractures in patients with prevalent fragility fractures: Current and future approaches.

S. Papapoulos, N. Appelman‐Dijkstra, 2013, Best practice & research. Clinical rheumatology.

Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism?

S. Papapoulos, N. Hamdy, A. V. van Lierop, 2012, European journal of endocrinology.

THURSDAY CONCURRENT SESSION # 1 S-1 . Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis : 5-Year Data from the Extension of the Phase 3 Long-term Odanacatib Fracture Trial ( LOFT )

D. Kiel, J. Manson, J. Cauley, 2016 .

Genome-wide association identifies three new susceptibility loci for Paget's disease of bone

F. Gianfrancesco, S. Ralston, M. Brandi, 2011, Nature Genetics.

Differential Effects of Aminosubstituted Analogs of Hydroxy Bisphosphonates on the Growth of Dictyostelium discoideum

S. Papapoulos, D. Watts, E. V. Beek, 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Control of hypercalcaemia in thyrotoxicosis

S. Papapoulos, M. Jones, 1979, Postgraduate medical journal.

New bone-forming treatments for osteoporosis

S. Papapoulos, 2016 .

Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research

T. Brown, P. Geusens, H. Genant, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Circulating 1,25-dihydroxycholecalciferol after intravenous injections of 1 alpha-hydroxycholecalciferol in patients on regular haemodialysis.

R. Valentijn, S. Papapoulos, M. Frölich, 1988, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Metabolic evaluation in stone patients in relation to extracorporeal shock wave lithotripsy treatment.

S. Papapoulos, H. Tan, G. A. Lycklama à Nijeholt, 1991, The Journal of urology.

Gene dose effect of a SOST mutation on circulating sclerostin and P1NP

S. Papapoulos, H. Hamersma, N. Hamdy, 2011 .